South Africa

Population 2018

<table>
<thead>
<tr>
<th>Numbers (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 3.4% (2.5–4.3)
- Previously treated cases: 7.1% (4.8–9.5)

TB case notifications, 2018

- Total new and relapse: 227 999
  - % tested with rapid diagnostics at time of diagnosis: 71%
  - % with known HIV status: 90%
  - % pulmonary: 89%
  - % bacteriologically confirmed MDR/RR: 70%
  - % children aged 0-14 years: 7%
  - % women: 37%
  - % men: 56%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 76% (57–110)
- TB patients facing catastrophic total costs: 22% (14–30)

HIV-positive TB incidence

- Number (thousands): 177 (127–235)
- Rate (per 100 000 population): 306 (219–406)

MDR/RR-TB incidence

- Number (thousands): 11 (7.2–16)
- Rate (per 100 000 population): 19 (12–28)

HIV-negative TB mortality

- Number (thousands): 21 (20–23)
- Rate (per 100 000 population): 37 (35–39)

HIV-positive TB mortality

- Number (thousands): 42 (30–57)
- Rate (per 100 000 population): 73 (51–99)

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 3.4% (2.5–4.3)
- Previously treated cases: 7.1% (4.8–9.5)

TB case notifications, 2018

- Total new and relapse: 227 999
  - % tested with rapid diagnostics at time of diagnosis: 71%
  - % with known HIV status: 90%
  - % pulmonary: 89%
  - % bacteriologically confirmed MDR/RR: 70%
  - % children aged 0-14 years: 7%
  - % women: 37%
  - % men: 56%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 76% (57–110)
- TB patients facing catastrophic total costs: 22% (14–30)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance MDR/RR: 92%
  - New cases: 92%
  - Previously treated cases: 94%

Laboratory-confirmed cases

- MDR/RR-TB: 13 199, XDR-TB: 553
- MDR/RR-TB: 9 558, XDR-TB: 539

MDR/RR-TB cases tested for resistance to second-line drugs

- Number: 7 469

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 77% (240 332)
- Previously treated cases, excluding relapse, registered in 2017: 59% (6 508)
- HIV-positive TB cases registered in 2017: 75% (134 672)
- MDR/RR-TB cases started on second-line treatment in 2016: 54% (11 159)
- XDR-TB cases started on second-line treatment in 2016: 58% (601)

Preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 65%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 59% (54–65)

TB financing, 2019

- National TB budget (US$ millions): 240
  - Funding source: 87% domestic, 13% international, 0% unfunded

* Ranges represent uncertainty intervals
* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
* MDR/RR: Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-01-22
Data: www.who.int/tb/data